2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2661

Physical Activity, Adiposity, and The Risk Of Gout In Women: The Nurses Health Study
Abstract Number: 1778

Physical Interactions Between Histidyl-tRNA Synthetase and Endogenous/Exogenous Alarmins Enhance Immunogenicity In a Model Of Antigen-Induced Myositis
Abstract Number: 2162

Physical, Psychological, and Social Impacts Of Restricting Back Pain: The Older Person’s Perspective
Abstract Number: 1483

Physician and Patient Characteristics Associated With The Decision To Treat Rheumatoid Arthritis Patients With Biologic Monotherapy In Usual Care Settings
Abstract Number: 1329

Physician Global Assessment At Three Months Is Strongly Predictive Of Remission At 12 Months In Early Rheumatoid Arthritis. Results From The Canadian Early Arthritis Cohort
Abstract Number: 1053

Physician Proclivity To Use Oral Glucocorticoids Among Rheumatoid Arthritis Patients
Abstract Number: 193

Physician Variability In Rheumatoid Patients Not Receiving Biologics Or Non-Biologic Dmards: Implications For Quality Reporting
Abstract Number: 2396

PI3Kdelta Regulates Invadosome Formation and Invasiveness Of Fibroblast-Like Synoviocyte In Rheumatoid Arthritis
Abstract Number: 2571

Pigment Epithelium Derived Factor Secreted By Activated Fibroblasts Can Contribute To Impaired Angio and Vasculogenesis In Scleroderma
Abstract Number: 1903

PIK3CD Overexpression In The Synovial Membrane Of Rheumatoid Arthritis Patients Is Associated With Response To Anti-TNF Therapy
Abstract Number: 2816

Pilot Phase Outcomes From The ACR/Carra Inter-Institutional Mentoring Program In Pediatric Rheumatology
Abstract Number: 2040

Pilot Study Of Abatacept In Patients With Refractory Autoimmune Chronic Urticaria
Abstract Number: 652

Pirfenidone and BIBF1120 Suppress Collagen Synthesis In Skin Fibroblast From Patients With Systemic Sclerosis
Abstract Number: 2124

Piriformis Muscle Syndrome: Diagnostic Criteria and Treatment Of a Monocentric Series Of 250 Cases
Abstract Number: 24

Plasma Cells In Acute Systemic Lupus Erythematosus Flares Are Characterized By a Highly Diversified Repertoire Accentuated By Clonal Expansions Of VH4-34 Antibodies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].